Palliative Surgery for Patients with Gastroesophageal Junction or Gastric Cancer: A Report on Clinical Observational Outcomes

被引:0
作者
Song, Yun [1 ]
Chen, Eunise [2 ]
Ikoma, Naruhiko [1 ]
Mansfield, Paul F. [1 ]
Bruera, Eduardo [3 ]
Badgwell, Brian D. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] UT Hlth, John P & Katherine G McGovern Med Sch, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Houston, TX USA
关键词
Palliative surgery; Palliative care; Gastric cancer; Gastroesophageal junction cancer; Metastatic cancer; Malignant obstruction; Clinical observational outcomes; QUALITY-OF-LIFE; SURGICAL PALLIATION; SURVIVAL; INDICATORS; INPATIENTS; MORBIDITY;
D O I
10.1245/s10434-024-15416-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFew studies have focused on palliative surgery in patients with advanced gastroesophageal junction (GEJ) or gastric cancer. We sought to evaluate clinical observational outcomes following palliative surgery in this population.Patients and MethodsPatients with GEJ or gastric cancer who underwent palliative surgery (1/2010-11/2022) were identified. The primary outcomes were symptom improvement, ability to tolerate an oral diet, discharge to home, 30 "good days" without hospitalization, and receipt of systemic treatment. Postoperative outcomes and survival were secondarily evaluated.ResultsAmong 93 patients, the median age was 59 (IQR 47-68) years, and the median Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was 1 (range 0-3). The most frequent indication for palliative surgery was primary tumor obstruction [75 (81%) patients]. The most common procedures were feeding tube placement in 60 (65%) and intestinal bypass in 15 (16%) patients. A total of 75 (81%) patients experienced symptom improvement. Of these, 19 (25%) developed recurrent and 49 (65%) developed new symptoms. ECOG-PS was significantly associated with symptom-free time. Among those who underwent a bypass, resection, or ostomy creation for malignant obstruction, 16 (80%) tolerated an oral diet. Postoperatively, 87 (94%) were discharged home, 72 (77%) had 30 good days, and 64 (69%) received systemic treatment. Postoperative complications occurred in 35 (38%) patients, and 7 (8%) died within 30 days. The median survival time was 7.7 (95% CI 6.4-10.40) months.ConclusionsPatients with incurable GEJ or gastric cancer can benefit from palliative surgery. Prognosis and performance status should inform goals-of-care discussions and patient selection for surgical palliation.
引用
收藏
页码:5252 / 5262
页数:11
相关论文
共 50 条
  • [21] Angiogenesis inhibitors in gastric and gastroesophageal junction cancer
    Roviello, Giandomenico
    Petrioli, Roberto
    Marano, Luigi
    Polom, Karol
    Marrelli, Daniele
    Perrella, Armando
    Roviello, Franco
    GASTRIC CANCER, 2016, 19 (01) : 31 - 41
  • [22] Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
    Valérie F. Cosson
    Vivian W. Ng
    Michaela Lehle
    Bert L. Lum
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 737 - 747
  • [23] Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)
    Kohei Shitara
    Ben George
    Julien Taieb
    Raghav Sundar
    Marwan G. Fakih
    Lukas Makris
    Karim A. Benhadji
    Michele Ghidini
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 9361 - 9374
  • [24] Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)
    Shitara, Kohei
    George, Ben
    Taieb, Julien
    Sundar, Raghav
    Fakih, Marwan G.
    Makris, Lukas
    Benhadji, Karim A.
    Ghidini, Michele
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 9361 - 9374
  • [25] Management and outcomes of localized esophageal and gastroesophageal junction cancer in older patients
    Qu, X.
    Biagi, J.
    Banashkevich, A.
    Mercer, C. D.
    Tremblay, L.
    Mahmud, A.
    CURRENT ONCOLOGY, 2015, 22 (06) : E435 - E442
  • [26] SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
    Martin-Richard, M.
    Carmona-Bayonas, A.
    Custodio, Ana. B.
    Gallego, J.
    Jimenez-Fonseca, P.
    Reina, J. J.
    Richart, P.
    Rivera, F.
    Alsina, M.
    Sastre, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (02) : 236 - 244
  • [27] A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
    Bell-Brown, Ari
    Hopkins, Talor
    Watabayashi, Kate
    Overstreet, Karen
    Leahy, Anthony
    Bradshaw, Erin
    Gallagher, Kathleen
    Obenchain, Jennifer
    Padron, Amber
    Scott, Beth
    Flores, Brooke
    Shankaran, Veena
    SUPPORTIVE CARE IN CANCER, 2024, 32 (03)
  • [28] Glasgow Prognostic Score is a Useful Predictive Factor for Palliative Surgery Outcomes in Advanced-stage Gastric Cancer
    Derici, Serhan
    Egeli, Tufan
    Cevlik, Ali
    Basara, Isil
    Unal, Sinan
    Sagol, Ozgul
    Atila, Koray
    CYPRUS JOURNAL OF MEDICAL SCIENCES, 2019, 4 (02): : 110 - 114
  • [29] Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
    Janmaat, Vincent T.
    Steyerberg, Ewout W.
    van der Gaast, Ate
    Mathijssen, Ron H. J.
    Bruno, Marco J.
    Peppelenbosch, Maikel P.
    Kuipers, Ernst J.
    Spaander, Manon C. W.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [30] Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
    Kubota, Yohei
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16